<DOC>
	<DOCNO>NCT01496430</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive antiglycemic effect , well safety tolerability TAK-491 ( azilsartan medoxomil ) , daily ( QD ) , stage 1 hypertensive , type 2 diabetes mellitus ( T2DM ) participant whose glycemic control inadequate metformin alone .</brief_summary>
	<brief_title>Efficacy Safety Azilsartan Medoxomil Used Combination With Metformin Participants With Hypertension Diabetes</brief_title>
	<detailed_description>The study include Screening Period 4 week , coincide 2-week single-blind , placebo Run-in Period , 24 week Treatment Period , 2-week Follow-up Period . The duration study approximately 30 week . The planned number participant ( n=450 ) reach ; actual enrollment consist 105 particpants . Due low enrollment study terminate early Takeda .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Was male female ≥18 year . 2 . Had type 2 diabetes mellitus HbA1c ≥7.5 ≤9.5 % Screening . 3 . Was treated metformin alone ( treatment antidiabetic agent metformin within 3 month prior Screening ) experience inadequate glycemic control . The participant receive metformin monotherapy ≥8 week prior Screening stable dose ≥1500 mg ) . Participants maximum tolerate dose ( MTD ) document less 1500 mg metformin could also enrol dose stable 8 week prior Screening . 4 . Was treated antihypertensive therapy mean , trough , sit clinic systolic blood pressure ( SBP ) ≥135 &lt; 160 mm Hg Day 1 ( washout prior antihypertensive therapy ) participant receive antihypertensive treatment within 28 day Screening mean sit clinic SBP ≥135 &lt; 160 mm Hg Screening Visit Day 1 . 5 . Had clinical laboratory evaluation ( include clinical chemistry , hematology , complete urinalysis ) within reference range test laboratory result deem clinically significant participant population inclusion study , investigator . 1 . Had mean , trough , sit clinic diastolic blood pressure ( DBP ) ≥ 100 mm Hg Day 1 . 2 . Had type 1 poorly control type 2 diabetes mellitus ( HbA1c &gt; 9.5 % ) Screening . 3 . Was take expected take exclude medication . 4 . Had history myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack . 5 . Had clinically significant cardiac conduction defect ( example , 3rd degree atrioventricular block , leave bundle branch block , sick sinus syndrome , atrial fibrillation ) . 6 . Had hemodynamically significant leave ventricular outflow obstruction due aortic valvular disease . 7 . Had secondary hypertension etiology ( e.g. , renovascular disease , pheochromocytoma , Cushing 's syndrome ) . 8 . Had renal dysfunction define estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 Screening . 9 . Had albuminuria define &gt; 200 mg/g Screening . 10 . Had know suspected unilateral bilateral renal artery stenosis . 11 . Had unexplained microhematuria ≥3 RBCs/HPF macrohematuria Screening confirm repeat testing . 12 . Treatment antidiabetic agent ( sulfonylurea , glucagonlike peptide1 ( GLP1 ) analogue , dipeptidyl peptidase4 ( DPP4 ) inhibitor , glinides , thiazolidinediones ( TZDs ) , and/or insulin ) metformin 3 month prior Screening . 13 . Had hyperkalemia define central laboratory normal reference range Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Drug Therapy</keyword>
	<keyword>Hypertension Diabetes</keyword>
</DOC>